Research progress in the relationship between abnormal blood glucose fluctuation and cognitive dysfunction of patients with diabetes mellitus

doi:10.3969/j.issn.1674-8115.2022.02.016

Abstract

Abstract:

Diabetes can not only cause pathological changes in both large vessels and microvessels, but also accelerate the occurrence and development of cognitive dysfunction, increasing the risk of dementia. Studies have shown that diabetes-induced cognitive dysfunction is associated with elevated blood glucose and abnormal glucose fluctuation, and its pathogenesis is closely related to insulin resistance, oxidative stress, cerebrovascular lesions, inflammatory damage, brain cell apoptosis, as well as amyloid β-protein accumulation. At present, drug therapy for diabetic patients with cognitive dysfunction is still in the exploratory stage. It has been found that some hypoglycemic drugs, such as glucagon like peptide -1 receptor agonist, can improve cognitive dysfunction in these patients. However, it still needs to be further clarified by randomized controlled trails with large sample size. This article reviews the assessment methods of cognitive dysfunction, the effects of abnormal glucose fluctuation on cognitive dysfunction, and the pathophysiological mechanisms involved, as well as the effects of different hypoglycemic agents on cognitive dysfunction in patients with diabetes.

Key words: diabetes mellitus, cognitive dysfunction, abnormal blood glucose fluctuation, hypoglycemic agent

CLC Number:

R587.1

Rong ZHANG, Li LU, Yaxin WANG, Wenqian DONG, Yu ZHANG, Jian ZHOU. Research progress in the relationship between abnormal blood glucose fluctuation and cognitive dysfunction of patients with diabetes mellitus[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 235-240.

TrendMD

References 43

1	中华医学会内分泌学分会, 余学锋, 赵家军, 等. 糖尿病患者认知功能障碍专家共识[J].中华糖尿病杂志, 2021, 13(7): 678-694.
2	XU W, CARACCIOLO B, WANG H X, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes[J]. Diabetes, 2010, 59(11): 2928-2935.
3	ZHENG F F, YAN L, YANG Z C, et al. HbA_1c, diabetes and cognitive decline: The English Longitudinal Study of Ageing[J]. Diabetologia, 2018, 61(4): 839-848.
4	ZHENG B, SU B W, PRICE G, et al. Glycemic control, diabetic complications, and risk of dementia in patients with diabetes: results from a large U.K. Cohort study[J]. Diabetes Care, 2021, 44(7): 1556-1563.
5	XIA W Q, LUO Y, CHEN Y C, et al. Glucose fluctuations are linked to disrupted brain functional architecture and cognitive impairment[J]. J Alzheimers Dis, 2020, 74(2): 603-613.
6	PALTA P, CARLSON M C, CRUM R M, et al. Diabetes and cognitive decline in older adults: the Ginkgo Evaluation of Memory Study[J]. J Gerontol A Biol Sci Med Sci, 2017, 73(1): 123-130.
7	BIESSELS G J, JANSSEN J, VAN DEN BERG E, et al. Rationale and design of the CAROLINA®-cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus[J]. BMC Neurol, 2018, 18(1): 7.
8	YANG X, CHEN Y Q, ZHANG W S, et al. Association between inflammatory biomarkers and cognitive dysfunction analyzed by MRI in diabetes patients[J]. Diabetes Metab Syndr Obes, 2020, 13: 4059-4065.
9	WANG H, TAN L, WANG H F, et al. Magnetic resonance spectroscopy in Alzheimer's disease: systematic review and meta-analysis[J]. J Alzheimers Dis, 2015, 46(4): 1049-1070.
10	ALOTAIBI A, TENCH C, STEVENSON R, et al. Investigating brain microstructural alterations in type 1 and type 2 diabetes using diffusion tensor imaging: a systematic review[J]. Brain Sci, 2021, 11(2): 140.
11	HU B, YAN L F, SUN Q, et al. Disturbed neurovascular coupling in type 2 diabetes mellitus patients: evidence from a comprehensive fMRI analysis[J]. Neuroimage Clin, 2019, 22: 101802.
12	DANNE T, NIMRI R, BATTELINO T, et al. International consensus on use of continuous glucose monitoring[J]. Diabetes Care, 2017, 40(12): 1631-1640.
13	BATTELINO T, DANNE T, BERGENSTAL R M, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42(8): 1593-1603.
14	LU J Y, MA X J, ZHANG L, et al. Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: a preliminary study[J]. Diabetes Res Clin Pract, 2020, 161: 108032.
15	LU J Y, MA X J, SHEN Y, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes[J]. Diabetes Technol Ther, 2020, 22(2): 72-78.
16	LU J Y, MA X J, ZHOU J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes[J]. Diabetes Care, 2018, 41(11): 2370-2376.
17	BECK R W, BERGENSTAL R M, RIDDLESWORTH T D, et al. Validation of time in range as an outcome measure for diabetes clinical trials[J]. Diabetes Care, 2019, 42(3): 400-405.
18	MAYEDA L, KATZ R, AHMAD I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e000991.
19	GUO Q Y, ZANG P, XU S Y, et al. Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA_1c in Chinese type 2 diabetes[J]. J Diabetes Res, 2020, 2020: 5817074.
20	RIZZO M R, MARFELLA R, BARBIERI M, et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients[J]. Diabetes Care, 2010, 33(10): 2169-2174.
21	ZHONG Y, ZHANG X Y, MIAO Y, et al. The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients[J]. Biomed Environ Sci, 2012, 25(1): 1-7.
22	DUNGAN K M, BUSE J B, LARGAY J, et al. 1, 5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes[J]. Diabetes Care, 2006, 29(6): 1214-1219.
23	RAWLINGS A M, SHARRETT A R, MOSLEY T H, et al. Glucose peaks and the risk of dementia and 20-year cognitive decline[J]. Diabetes Care, 2017, 40(7): 879-886.
24	QUINCOZES-SANTOS A, BOBERMIN L D, DE ASSIS A M, et al. Fluctuations in glucose levels induce glial toxicity with glutamatergic, oxidative and inflammatory implications[J]. Biochim Biophys Acta Mol Basis Dis, 2017, 1863(1): 1-14.
25	MAIORINO M I, CASCIANO O, VOLPE E D, et al. Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study[J]. Endocrine, 2016, 52(2): 244-252.
26	WANG H, DENG J L, CHEN L, et al. Acute glucose fluctuation induces inflammation and neurons apoptosis in hippocampal tissues of diabetic rats[J]. J Cell Biochem, 2019. doi: 10.1002/jcb.29523.
27	HSIEH C F, LIU C K, LEE C T, et al. Acute glucose fluctuation impacts microglial activity, leading to inflammatory activation or self-degradation[J]. Sci Rep, 2019, 9(1): 840.
28	KSHIRSAGAR V, THINGORE C, JUVEKAR A. Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder[J]. Metab Brain Dis, 2021, 36(1): 67-83.
29	NGUYEN T T, TA Q T H, NGUYEN T K O, et al. Type 3 diabetes and its role implications in Alzheimer's disease[J]. Int J Mol Sci, 2020, 21(9): 3165.
30	刘涵, 侯新国, 陈丽. 关于2型糖尿病患者认知功能障碍机制的研究进展[J]. 中华糖尿病杂志, 2021, 13(7): 737-739.
31	JO D, YOON G, SONG J. Role of exendin-4 in brain insulin resistance, mitochondrial function, and neurite outgrowth in neurons under palmitic acid-induced oxidative stress[J]. Antioxidants (Basel), 2021, 10(1): 78.
32	CUKIERMAN-YAFFE T, GERSTEIN H C, COLHOUN H M, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial[J]. Lancet Neurol, 2020, 19(7): 582-590.
33	ZHANG Z, ZHANG B, WANG X, et al. Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies[J]. Diabetes Care, 2019, 42(7): 1274-1283.
34	BIESSELS G J, VERHAGEN C, JANSSEN J, et al. Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA Randomized Trial[J]. Diabetes Care, 2019, 42(10): 1930-1938.
35	ATES BULUT E, SAHIN ALAK Z Y, DOKUZLAR O, et al. Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study[J]. Arch Gerontol Geriatr, 2020, 88: 104013.
36	HIERRO-BUJALANCE C, INFANTE-GARCIA C, MARCO ADEL, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes[J]. Alzheimers Res Ther, 2020, 12(1): 40.
37	PERNA S, MAINARDI M, ASTRONE P, et al. 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with type-2 diabetes mellitus[J]. Clin Pharmacol, 2018, 10: 141-151.
38	CUKIERMAN-YAFFE T, BOSCH J, DIAZ R, et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial[J]. Lancet Diabetes Endocrinol, 2014, 2(7): 562-572.
39	WEINSTEIN G, DAVIS-PLOURDE K L, CONNER S, et al. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: pooled analysis from 5 cohorts[J]. PLoS One, 2019, 14(2): e0212293.
40	SAMARAS K, MAKKAR S, CRAWFORD J D, et al. Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study[J]. Diabetes Care, 2020, 43(11): 2691-2701.
41	DE LA MONTE S M, TONG M, WANDS J R. The 20-year voyage aboard the journal of Alzheimer's disease: docking at 'type 3 diabetes', environmental/exposure factors, pathogenic mechanisms, and potential treatments[J]. J Alzheimers Dis, 2018, 62(3): 1381-1390.
42	XUE M, XU W, OU Y N, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies[J]. Ageing Res Rev, 2019, 55: 100944.
43	BURNS D K, ALEXANDER R C, WELSH-BOHMER K A, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2021, 20(7): 537-547.

[1]	Qin GU, Yingqian XIA, Yiqing ZHU, Liying MA, Lei QU, Wenguang SUN. Analysis of the effects of individualized one-day outpatient diet guidance on glycemic control, body weight gain rate and pregnancy outcome in pregnant women with gestational diabetes mellitus [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 185-191.
[2]	Jing-jing ZHANG, Chao-yu ZHU, Yuan-yuan XIAO, Fu-song JIANG, Qing-ge GAO, Yun-yun FANG, Li WEI. Association study of variation of glucagon-like peptide-1 receptor gene rs3765467 and type 2 diabetes mellitus [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(9): 1215-1221.
[3]	Dan WU, Li-ping GE. Research progress of DNA methylation in gestational diabetes mellitus [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1120-1124.
[4]	Jia-si ZHANG, Chun-bo ZOU, Yu LU, Xi CHEN, Wei-ya ZHANG, Jiao-jiao HE. Value of blood lipoprotein phospholipase A2 and neutrophil gelatinase-associated lipocalin in the diagnosis of early diabetic nephropathy [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 770-775.
[5]	Shu-jun WAN, Xiang KONG, Kun LÜ. Relationship between non-coding RNAs and vascular diseases of diabetes mellitus [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 665-670.
[6]	Yue-hua TU, Xiao-jin WANG, Bing-shun WANG. Effects of individualized nutritional standard meal intervention on the prevention of gestational diabetes in overweight and obese pregnant women [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 360-365.
[7]	Qing LIU, Wen CAI, Rui-qing ZHANG, Cong LU, Jia-rong ZHANG, Xian-ming XU. Value of pregnancy lipid tolerance test in predicting risk of gestational diabetes mellitus [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 210-216.
[8]	Yuan-sen DING, Feng WANG, Jia-yue SUN, Zheng-wei SHAO, De-rong ZOU, Jia-yu LU. Epidemiological survey of periodontal health in patients with type 2 diabetes mellitus of different ages [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 217-222.
[9]	Song-tao ZHANG, Yuan-yuan XIAO, Hui GUO, Qing-ge GAO, Li WEI. Klinefelter syndrome combined with diabetes mellitus: a case report and literature review [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 126-128.
[10]	Ya-jie ZHU, Hui LIN, Xi CHEN, Yi-ran ZHAO, Xin-mei LIU, He-feng HUANG. Change of cortisol level in umbilical cord blood of neonates delivered by gestational diabetes mellitus mothers and its influence on offspring health [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 49-54.
[11]	CHEN Shuai, DING Feng-hua, DAI Yang, LU Lin, SHEN Ying, SHEN Wei-feng. Research progress in involvement of inflammatory cells in formation of coronary collateral circulation [J]. , 2020, 40(3): 380-.
[12]	GUO Yan-yan, GUO Fei, LI Tong, LI Yu-chen, HUANG He-feng, LIU Xin-mei. Changes and significance of coagulation indexes in pregnant women with gestational diabetes mellitus [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1614-1617.
[13]	LUO Gang, CUI Yong-chen, CAO Yue, ZHANG Jun-feng. Effect of surgical trauma on postoperative cognitive function and cerebral glucose metabolism in type 2 diabetic mice [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1468-1472.
[14]	YU Meng-na1, YANG Biao2, YANG Li-zhen1. Prediction and bioinformatics analysis of hsa-miR-223-3p target genes related to diabetes mellitus [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1477-1484.
[15]	LIN Hao, PAN Jian-an, ZHANG Jun-feng, GU Jun, WANG Chang-qian. Effects of different treatment regiments for diabetes mellitus, hypertension and atrial fibrillation on the risk of heart failure with preserved ejection fraction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1402-1407.